Kintara Q2 net loss $1.0M; starts REM-001 CMBC study, explores strategic alternatives

TuHURA Biosciences, Inc./NV

2024-FY EPS reported -$2.47

Q2 net loss $1.0M ($0.24/share) vs $3.5M ($2.10/share) year earlier; R&D fell to $0.1M from $2.1M.
Cash $0.7M at Dec 31, 2023; raised $6.1M net via ATM from Jan 1-Feb 12, 2024.
Initiated 15-patient REM-001 study in cutaneous metastatic breast cancer; costs covered by $2.0M SBIR grant from NIH.
Board reviewing strategic alternatives to maximize stockholder value; Ladenburg Thalmann engaged as financial advisor (Dec 2023).
VAL-083 development terminated after failure in GBM AGILE study (Oct 2023).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

TuHURA Biosciences, Inc./NV reported fiscal 2024 second quarter ended December 31, 2023 results: net income $1.0 million, EPS $0.24 per share.

Period: fiscal 2024 second quarter ended December 31, 2023
Net income: $1.0 million
EPS: $0.24 per share
Result: reported results

Exact text from the filing

For the three months ended December 31, 2023, Kintara reported a net loss of approximately $1.0 million, or $0.24 per share

View on SEC.gov

9 earnings releases filed in the last 30 days. Browse all earnings releases →

TuHURA Biosciences, Inc./NV filing history →

Source: SEC EDGAR

accession 0000950170-24-015213

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.